Definitions

from Wiktionary, Creative Commons Attribution/Share-Alike License

  • n. A particular antihistamine drug used in eye drops to treat allergic conjunctivitis.

Etymologies

Sorry, no etymologies found.

Examples

  • Elestat® is a sterile ophthalmic solution containing epinastine that is indicated for the prevention of ocular itching associated with allergic conjunctivitis.

  • Elestat, or epinastine solution, is used to treat itchiness caused by an eye allergy linked to exposure to tree pollen, grass and plants, animal dander, feathers, dust mites and molds.

  • Inspire receives revenues related to the promotion of AZASITE for bacterial conjunctivitis, the co-promotion of ELESTAT ® (epinastine HCl ophthalmic solution) 0.05% for allergic conjunctivitis and royalties based on net sales of RESTASIS ® (cyclosporine ophthalmic emulsion) 0.05% for dry eye and DIQUAS™ Ophthalmic Solution 3% (diquafosol tetrasodium) for dry eye.

  • Total product co-promotion and royalty revenue, comprised of royalty revenue from net sales of RESTASIS® (cyclosporine ophthalmic emulsion) 0. 05% and co-promotion revenue from net sales of ELESTAT® (epinastine HCl ophthalmic solution) 0. 05%, was $17.5 million for the fourth quarter of 2009, compared to

    The Earth Times Online Newspaper

  • Inspire receives revenues related to the promotion of AZASITE for bacterial conjunctivitis, the co-promotion of ELESTAT® (epinastine HCl ophthalmic solution) 0. 05% for allergic conjunctivitis and royalties based on net sales of RESTASIS® (cyclosporine ophthalmic emulsion) 0. 05% for dry eye.

    The Earth Times Online Newspaper

  • Co-promotion revenue from ELESTAT will be dependent on the timing of a launch of a generic form of epinastine, which could occur in 2010.

    The Earth Times Online Newspaper

  • Inspire receives revenues related to the promotion of AZASITE for bacterial conjunctivitis, the co-promotion of ELESTAT® (epinastine HCl ophthalmic solution) 0.05% for allergic conjunctivitis and royalties based on net sales of RESTASIS® (cyclosporine ophthalmic emulsion) 0.05% for dry eye.

    Inspire Announces Date for Conference Call and Webcast to Discuss Third Quarter 2010 Financial Results - Yahoo! Finance

  • Based upon historical timelines and our understanding of the FDA review cycle, we do not expect a generic epinastine product to launch in 2009.

    Biotech Sector and Stocks Analysis from Seeking Alpha

  • Upon completing an evaluation of the situation Boehringer Ingelheim, the owner of the Elestat patent decided not to pursue or file suit against the companies currently seeking approval of a generic epinastine product.

    Biotech Sector and Stocks Analysis from Seeking Alpha

  • Recently we have reported that several ANDA filings for a generic version of epinastine were filed with the FDA.

    Biotech Sector and Stocks Analysis from Seeking Alpha

Comments

Log in or sign up to get involved in the conversation. It's quick and easy.